A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

ISSN： 1439-7595

Source： Modern Rheumatology, Vol.22, Iss.2, 2012-04, pp. : 298-302

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review

Current Rheumatology Reviews, Vol. 8, Iss. 3, 2012-08 ,pp. : 209-226

Bentham Science Publishers

Access to resources Recommend Favorite

IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab

Current Rheumatology Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 288-300

Bentham Science Publishers

Access to resources Recommend Favorite

Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: areportofthree cases

By Komaba Hirotaka Nakazawa Takashi Yamaguchi Yutaka Kumagai Shunichi Fukagawa Masafumi

NDT PLUS, Vol. 1, Iss. 6, 2008-12 ,pp. : 423-426

Oxford University Press

Access to resources Recommend Favorite

The OPTION trial: inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis

By Ramos-Remus Cesar Muriel-Vizcaino Rodolfo

Future Rheumatology, Vol. 3, Iss. 5, 2008-10 ,pp. : 429-434

Future Medicine

Access to resources Recommend Favorite

Treatment of Crohn’s disease with anti-IL-6 receptor antibody

By Ito Hiroaki

Journal of Gastroenterology, Vol. 40, Iss. 16, 2005-01 ,pp. : 32-34

Springer Publishing Company

Access to resources Recommend Favorite